Pooled sputum testing found workable where laboratory systems were already prepared
Pooled sputum testing for tuberculosis moved from a resource-saving concept to a practical diagnostic option in this multicountry qualitative study, but only under the right conditions. Across facility and community settings in Bangladesh, Brazil, Cameroon, Kenya, Malawi, Nigeria, and Viet Nam, stakeholders described the approach as both feasible and acceptable when laboratories, national programs, and frontline staff were aligned. The central message was not that pooling should be dropped into any clinic without adjustment. It was that the method can function as a sensible way to stretch molecular testing capacity when existing systems are stable enough to absorb it.
The study drew on 38 key informant interviews and 18 focus group discussions with National TB Programme representatives, laboratory technicians, people with TB, and international experts. Their reflections map closely to the real bottlenecks in TB diagnosis: high assay costs, limited access to molecular platforms, and uneven uptake of rapid testing. In many high-burden settings, only half of people with TB receive a molecular test as their initial diagnostic test, leaving a large diagnostic gap before treatment can even begin. Pooling sputum samples into a single molecular assay addresses the pressure point directly by reducing reagent use and preserving scarce laboratory capacity.
Feasibility depended on workflow fit, biosafety, and clear operating rules
The most consistent finding was operational. Stakeholders judged pooled testing feasible when it fit into diagnostic algorithms without disrupting the lab chain. In practice, that means the strategy cannot sit outside the logic of specimen receipt, batching, assay processing, result reporting, and follow-up. Laboratories needed biosafety safeguards, staff training, and standard operating procedures that made the pooled process predictable rather than improvised.
A single workflow mismatch can erode the value of a cost-saving tool.
That concern ran through the interviews and discussions. Where countries had prior experience with pooled testing, confidence was higher because staff had already seen how the approach behaves in routine conditions. Experience mattered because pooling changes how technicians think about specimen triage and result interpretation. A negative pooled result may clear multiple patients at once, while a positive pool triggers downstream testing to identify the individual source. The method therefore relies on disciplined laboratory execution, not just on the chemistry of the assay itself.
The study also makes clear why biosafety appears so central. Sputum is a potentially infectious specimen, and pooling increases the need for careful handling at the bench. When laboratory staff trust the safety steps and understand each movement in the process, the method looks manageable. When procedures are vague or training is thin, the same strategy can feel risky and disruptive, even if the underlying assay is sound.
Acceptance rose when programs and providers were engaged early
Acceptability operated on two levels. At the program level, early engagement of National TB Program teams with healthcare providers helped secure professional buy-in. At the patient level, clear communication between providers and people being tested helped explain why multiple samples might be combined and how results would still lead to appropriate care. Both levels matter because pooled testing changes the experience of diagnosis for staff and patients at the same time.
Healthcare workers are unlikely to adopt a new diagnostic routine if it appears to complicate clinic flow or introduce uncertainty into reporting. Patients, meanwhile, need to understand that pooling is not a compromise in quality but a strategy to improve access. In settings where communication was strong, the method was easier to accept. In settings where it was not, hesitation was more likely, even when the technical infrastructure existed.
This social dimension is easy to miss when the conversation stays focused on assay economics. Yet TB diagnosis depends on trust. People already navigating stigma, delayed care, and repeated visits are more likely to accept a testing strategy when clinicians explain it plainly and consistently. A pooled test may save money, but it also has to preserve confidence in the diagnostic pathway.
Countries with prior experience were closer to rapid scale-up
Readiness varied sharply across the seven countries. Some settings appeared ready for rapid implementation and scale-up, while others needed system strengthening before the method could be expanded. The difference was not simply whether a molecular platform existed. It was whether the surrounding system could support pooling as a routine practice. Robust laboratory systems, established workflows, trained personnel, and routine habits around molecular TB testing made a major difference in perceived readiness.
In countries with stronger systems, pooled testing was viewed as a pragmatic route to optimize the use of molecular assays already in place. In weaker systems, the same strategy was seen as dependent on preparatory work: aligning algorithms, clarifying responsibilities, tightening biosafety procedures, and building staff confidence. This is the kind of implementation gap that often determines whether a low-cost innovation becomes a daily practice or remains a pilot project.
The biological logic behind pooled testing is straightforward. Molecular assays are sensitive enough to detect TB DNA in combined samples when the pool size and lab process are appropriate. The health-system logic is more demanding. The diagnostic pathway must preserve sensitivity, avoid confusion about follow-up testing, and keep turnaround times manageable. If any of those steps falter, the theoretical savings may be offset by delays or operational friction.
WHO recommendation meets a heterogeneous real-world environment
The World Health Organization recommended pooled sputum testing in 2026, but this study shows why a global recommendation does not produce uniform readiness on its own. The countries in this project were all high-burden settings, yet their practical capacity differed enough to shape how stakeholders judged the method. Some systems were prepared to adopt it quickly. Others needed targeted strengthening before pooling could be used safely and consistently at scale.
That gap has concrete implications for TB control. Pooled testing may help expand access to molecular diagnostics where resources are limited, but adoption will depend on local lab structure and staff preparedness rather than on policy alone. Program leaders will need to decide where pooling can be introduced immediately and where investments in training, biosafety, and workflow redesign should come first.
For clinicians and TB program managers, the study offers a clear operational message: pooled sputum testing is not an abstract efficiency exercise. It is a diagnostic strategy that works when infrastructure, communication, and governance are already doing some of the heavy lifting. Where those elements are in place, the method can extend molecular testing further than current practice allows. Where they are missing, the path to implementation remains longer and more fragile.